GLP-1 receptor agonists work by mimicking the glucagon-like peptide-1 hormone stimulating insulin release, reducing appetite, and slowing gastric emptying
Verify current pricing on the official website, as program structures and pricing may change
MDL 3094 has been filed against Ozempic, Wegovy, and Rybelsus manufacturer Novo Nordisk as well as Trulicity and Mounjaro manufacturer Eli Lilly and Company
Regular monitoring of HbA1c, kidney function, and potential complications such as pancreatitis is essential
Regular monitoring, including review of symptoms, weight, HbA1c, and appropriate screening for diabetic retinopathy in those with pre-existing disease, enables early identification and management of adverse effects whilst optimising therapeutic outcomes
Regular follow-ups help ensure the treatment is workingand that your body is tolerating it well